Please join Sidley for the Boston Life Sciences Roundtable, comprised of three virtual sessions, each addressing cutting-edge trends and hot topics. Our first session features a timely discussion of what the political changes in Washington, D.C. mean for life sciences companies in 2021 and beyond. More info to come on second and third sessions.
WHO MAY BE INTERESTED IN ATTENDING
Executives, Investors, General Counsel, and Company Counsel
No Passport Required: Tapping into Global Biopharma Opportunities
Thursday, March 18, 2021
9:00 a.m. PT | 11:00 a.m. CT | 12:00 p.m. ET
How does a biopharma company – big or small – succeed globally?
Capital markets from the U.S. to Hong Kong are booming, innovation and expertise are springing up in even more locations, and unmet medical needs have never been more urgently global. For biopharma companies, opportunities abound – as do challenges. Expect from this panel a wide-ranging discussion on successfully managing global expansion, including: evaluating private and public financing alternatives; structuring non-U.S. partnering deals; building broad supply and distribution chains; managing worldwide clinical and regulatory activities; and developing a sound governmental affairs strategy.
Tom Duley, Partner, Technology and IP Transactions
Geoffrey Levin, Partner, Private Equity
Asher Rubin, Partner, M&A
Becky Wood (Moderator), Partner, Food, Drug and Medical Device Regulatory and former Chief Counsel, FDA
What the New Administration and New Congress Mean for the Life Sciences Industry
January 26, 2021
9:00 a.m. - 10:00 a.m. PT | 11:00 a.m. - 12:00 p.m. CT | 12:00 p.m. - 1:00 p.m. ET
Join us for a timely discussion of what the political changes in Washington, D.C. mean for life sciences companies in 2021 and beyond:
- Overview of the seismic shifts underway in Washington, D.C.
- Congressional priorities and investigations landscape
- Impact on major FDA initiatives: COVID-19 response, novel therapy approvals, gene therapy, real-world evidence
- FDA’s upcoming compliance and enforcement focus
Michael Borden, Partner, Government Strategies and former Senior Counsel, House Financial Services Committee
Deeona Gaskin, Partner, Food, Drug and Medical Device Compliance and Enforcement and former Associate Chief Counsel for Enforcement, FDA
Congressman (Ret.) Peter Roskam, Partner, Government Strategies Practice and former six-term U.S. Representative
Becky Wood, Partner, Food, Drug and Medical Device Regulatory and former Chief Counsel, FDA
For more information, contact firstname.lastname@example.org.